Yi Zeng1, Yutong Ye2, Desen Liang2, Chao Guo1, Lijie Li3. 1. Department of Pharmacy, Guigang People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University Guigang 537100, Guangxi, Zhuang Autonomous Region, P. R. China. 2. Department of Pharmacy, Youjiang Medical University for Nationalities Baise 533000, Guangxi, Zhuang Autonomous Region, P. R. China. 3. School of Public Policy and Administration, Xi'an Jiaotong University Xi'an 710049, Shaanxi Province, P. R. China.
Abstract
OBJECTIVE: To conduct a systematic evaluation of the efficacy of lansoprazole and omeprazole for the treatment of Helicobacter pylori-associated duodenal ulcer. METHODS: Online databases, including CHKD, VIP, China Info, the National Digital Library of China, Google Scholar, PubMed, Lippincott Williams & Wilkins, and Wiley Online Library were searched for related studies. The quality of the studies was evaluated in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, and relevant information was extracted from them. The studies were subjected to meta-analysis using RevMan5.3 software, and qualitative analysis was performed for studies, in which the data could not be merged. RESULTS: A total of nine randomized controlled trials (RCTs) were included, all of which presented the possibility of bias. Meta-analysis showed no significant differences between patients treated with lansoprazole combinations and omeprazole combinations in terms of DU healing rate (RR = 1.04, 95% CI = 0.99~1.09, P = 0.93). There were significant differences between those treated by lansoprazole combination and omeprazole combination in terms of HP eradication rate (RR = 1.09, 95% CI = 1.01~1.18, P = 0.04), and there was no serious adverse reaction during the treatment process for both lansoprazole and omeprazole. CONCLUSION: Lansoprazole and omeprazole exhibit similar efficacy in the treatment of Helicobacter pylori associated duodenal ulcers.
OBJECTIVE: To conduct a systematic evaluation of the efficacy of lansoprazole and omeprazole for the treatment of Helicobacter pylori-associated duodenal ulcer. METHODS: Online databases, including CHKD, VIP, China Info, the National Digital Library of China, Google Scholar, PubMed, Lippincott Williams & Wilkins, and Wiley Online Library were searched for related studies. The quality of the studies was evaluated in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, and relevant information was extracted from them. The studies were subjected to meta-analysis using RevMan5.3 software, and qualitative analysis was performed for studies, in which the data could not be merged. RESULTS: A total of nine randomized controlled trials (RCTs) were included, all of which presented the possibility of bias. Meta-analysis showed no significant differences between patients treated with lansoprazole combinations and omeprazole combinations in terms of DU healing rate (RR = 1.04, 95% CI = 0.99~1.09, P = 0.93). There were significant differences between those treated by lansoprazole combination and omeprazole combination in terms of HP eradication rate (RR = 1.09, 95% CI = 1.01~1.18, P = 0.04), and there was no serious adverse reaction during the treatment process for both lansoprazole and omeprazole. CONCLUSION:Lansoprazole and omeprazole exhibit similar efficacy in the treatment of Helicobacter pylori associated duodenal ulcers.
Entities:
Keywords:
HP infection; Lansoprazole; duodenal ulcer; meta-analysis; omeprazole
Authors: A W Harris; J J Misiewicz; K D Bardhan; S Levi; C O'Morain; B T Cooper; G D Kerr; M F Dixon; H Langworthy; D Piper Journal: Aliment Pharmacol Ther Date: 1998-08 Impact factor: 8.171